Skip to main content

Table 3 Baseline characteristics of the studies which were included in this analysis

From: Bleeding events associated with a low dose (110 mg) versus a high dose (150 mg) of dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis

Studies

Mean age (y)

Males (%)

Hypertension (%)

DM (%)

Previous stroke/TIA (%)

 

110/150 mg

110/150 mg

110/150 mg

110/150 mg

110/150 mg

Connolly2013 [22]

71.0/71.0

66.0/65.0

80.0/78.0

23.0/22.0

20.0/21.0

Eikelboon2013 [23]

71.4/71.5

64.3/63.2

78.8/78.9

23.4/23.1

19.9/20.3

Larsen2013 [24]

74.7/67.4

46.9/61.5

18.0/22.7

10.8/12.1

17.5/17.1

Maura2015 [25]

77.4/66.1

48.0/66.0

83.0/74.0

20.0/18.0

8.0/6.0

Nishtala2016 [26]

77.3/77.3

53.1/53.1

-

15.6/15.6

18.8/18.8

  1. Abbreviations: y year, DM diabetes mellitus, TIA transient ischemic attack, 110 mg 110 mg of dabigatran, 150 mg 150 mg of dabigatran